In clinical trials
Digestive & weight
Pemvidutide
Evidence
Clinical trials
Class
Dual GLP-1 and glucagon receptor agonist
KEY TAKEAWAY
Pemvidutide is a peptide that activates both the GLP-1 and glucagon receptors. Altimmune is developing it for fatty liver disease and obesity. Pemvidutide is not FDA-approved and is being tested in clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Dual GLP-1 and glucagon receptor agonist
Being studied for
Studied for fatty liver disease (MASH) and obesity
Key fact
Pemvidutide is not FDA-approved and is being tested in clinical trials.
Route
Weekly subcutaneous injection in trials
Evidence strength
Clinical trials
Pemvidutide is a peptide that activates both the GLP-1 and glucagon receptors. Altimmune is developing it for fatty liver disease and obesity.
GLP-1 activity reduces appetite, while glucagon activity may increase energy use and lower fat stored in the liver.
Pemvidutide is not FDA-approved and is being tested in clinical trials.
Studied for fatty liver disease (MASH) and obesity.
Nausea, vomiting and diarrhea were the most common effects in trials.
Pemvidutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.